Pfizer and BioNTech Close in COVID-19 Vaccine With This Next Big Step

Health and Healthcare

Published: July 28, 2020 8:46 am

Last Updated: October 16, 2020 10:36 am

Pfizer Inc. (NYSE: PFE) and BioNTech S.E. (NASDAQ: BNTX) made another big step in their fight against COVID-19 by initiating their late-stage study for their lead mRNA vaccine candidate. This trial will be testing the safety and efficacy with up to 30,000 participants around the world.

In terms of the specifics, the Phase 2/3 safety and efficacy clinical study will evaluate a single nucleoside-modified messenger RNA candidate from the BNT162 mRNA-based vaccine program, against SARS-CoV-2.

After review of the preclinical and clinical data from the Phase 1/2 clinical trial and consulting with the U.S. Food and Drug Administration (FDA), among other global regulators, Pfizer and BioNTech are advancing their BNT162b2 vaccine candidate. Note that BNT162b2 recently received Fast Track designation from the FDA. BNT162b2 encodes an optimized SARS-CoV-2 full-length spike glycoprotein, which is the target of virus-neutralizing antibodies.

The companies selected BNT162b2 as the lead candidate for this Phase 2/3 trial upon evaluation of the totality of the data generated so far. Management said that this decision reflects the primary goal to bring a well-tolerated, highly effective vaccine to the market as quickly as possible.

Pfizer and BioNTech will continue to evaluate their other vaccine candidates as part of a differentiated COVID-19 vaccine portfolio

Pfizer stock closed Monday at $37.54, in a 52-week range of $27.88 to $43.00. The consensus price target is $40.25. The stock was up about 2.8% at $38.61 in early trading indications Tuesday.

BioNTech stock recently closed at $86.53 and has a 52-week range of $12.52 to $105.00. Analysts have a consensus price target of $62.08. The stock was up 2.6% at $88.80 in early indications Tuesday.

24/7 Wall St.
Top Strategists Say Sell Expensive Tech Giants and Buy Cheap Cyclicals Now

The Average American Has No Idea How Much Money You Can Make Today ^(Sponsor)

The last few years made people forget how much banks and CD’s can pay. Meanwhile, interest rates have spiked and many can afford to pay you much more, but most are keeping yields low and hoping you won’t notice.

But there is good news. To win qualified customers, some accounts are paying almost 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.

Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 4.00% with a Checking & Savings Account from Sofi. Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

¹https://www.fdic.gov/national-rates-and-rate-caps